Wall Street analysts expect that Sarepta Therapeutics Inc (NASDAQ:SRPT) will report sales of $56.22 million for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Sarepta Therapeutics’ earnings. The highest sales estimate is $57.70 million and the lowest is $54.50 million. Sarepta Therapeutics posted sales of $5.42 million during the same quarter last year, which would indicate a positive year over year growth rate of 937.3%. The firm is expected to issue its next earnings results on Tuesday, February 27th.

On average, analysts expect that Sarepta Therapeutics will report full year sales of $56.22 million for the current fiscal year, with estimates ranging from $151.81 million to $155.00 million. For the next fiscal year, analysts expect that the business will report sales of $307.74 million per share, with estimates ranging from $267.20 million to $363.90 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow Sarepta Therapeutics.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.66. The business had revenue of $45.95 million during the quarter, compared to the consensus estimate of $41.29 million. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. During the same period in the previous year, the company posted ($0.95) EPS.

A number of research firms have issued reports on SRPT. Zacks Investment Research downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday. HC Wainwright began coverage on Sarepta Therapeutics in a research note on Friday, December 1st. They set a “buy” rating and a $75.00 price target for the company. Needham & Company LLC restated a “buy” rating on shares of Sarepta Therapeutics in a research note on Friday, October 27th. Barclays lifted their price objective on Sarepta Therapeutics from $46.00 to $49.00 and gave the company an “equal weight” rating in a research report on Thursday, October 26th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating on shares of Sarepta Therapeutics in a research report on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and sixteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $64.14.

In related news, SVP Shamim Ruff sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $55.00, for a total value of $550,000.00. Following the transaction, the senior vice president now directly owns 37,045 shares of the company’s stock, valued at approximately $2,037,475. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the business’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $55.89, for a total value of $372,618.63. Following the completion of the transaction, the director now directly owns 13,333 shares in the company, valued at $745,181.37. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,167 shares of company stock worth $1,497,619. 9.60% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of SRPT. Ameritas Investment Partners Inc. increased its stake in Sarepta Therapeutics by 6.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after acquiring an additional 271 shares during the last quarter. Cubist Systematic Strategies LLC increased its stake in Sarepta Therapeutics by 116.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after acquiring an additional 2,474 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. increased its stake in Sarepta Therapeutics by 140.9% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock worth $193,000 after acquiring an additional 2,493 shares during the last quarter. Fox Run Management L.L.C. bought a new stake in Sarepta Therapeutics in the 3rd quarter worth approximately $204,000. Finally, Bayesian Capital Management LP bought a new stake in Sarepta Therapeutics in the 2nd quarter worth approximately $206,000. 82.02% of the stock is currently owned by institutional investors.

Sarepta Therapeutics (SRPT) traded up $1.49 during trading on Monday, hitting $54.09. The company’s stock had a trading volume of 1,536,756 shares, compared to its average volume of 2,269,130. Sarepta Therapeutics has a 1-year low of $26.26 and a 1-year high of $57.57. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/sarepta-therapeutics-inc-srpt-expected-to-post-quarterly-sales-of-56-22-million/1771659.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.